Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 13, Number 11—November 2007

Research

Methamphetamine Use and Methicillin-Resistant Staphylococcus aureus Skin Infections

Adam L. Cohen*Comments to Author , Carrie Shuler*†, Sigrid McAllister*, Gregory E. Fosheim*, Michael G. Brown‡, Debra Abercrombie§, Karen Anderson*, Linda K. McDougal*, Cherie Drenzek†, Katie Arnold†, Daniel Jernigan*, and Rachel Gorwitz*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Georgia Division of Public Health, Atlanta, Georgia, USA; ‡Kennestone Hospital, Marietta, Georgia, USA; §Northwest Georgia Health District 1–1, Rome, Georgia, USA;

Main Article

Table 3

Antimicrobial susceptibility patterns and toxin gene presence of selected MRSA and MSSA isolates*

Antimicrobial agent or toxin MRSA isolates† (N = 32), no. (%) MSSA isolates (N = 13), no. (%)
Antimicrobial susceptibility
Chloramphenicol 32 (100.0) 10 (76.9)‡
Clindamycin 32 (100.0) 12 (92.3)
Inducible resistance (D-zone test) 0 1 (7.7)
Daptomycin 32 (100.0) 13 (100.0)
Doxycycline 32 (100.0) 13 (100.0)
Erythromycin 2 (6.5) 6 (46.2)
Gentamicin 32 (100.0) 13 (100.0)
Levofloxacin 27 (84.4) 12 (92.3)
Linezolid 32 (100.0) 13 (100.0)
Penicillin 0 2 (15.4)
Rifampin 32 (100.0) 13 (100.0)
Trimethoprim-sulfamethoxazole 32 (100.0) 13 (100.0)
Vancomycin 32 (100.0) 13 (100.0)
Toxin gene presence
Panton-Valentine leukocidin 32 (100.0) 5 (38.5)
TSST–1 0 0

*MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; TSST, toxic shock syndrome toxin.
†Methicillin resistance was determined by the oxacillin MIC and disk diffusion using a 30-μg cefoxitin disk (14).
‡Three (23.1%) isolates had intermediate resistance to chloramphenicol.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO